Deal Watch: Altimmune Moves Into NASH With Purchase Of Spitfire

 
• By Joseph Haas, Alexandra Shimmings, and John Davis

Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.

DealWatch_1200x675

More from Deals

More from Business